Trial Profile
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Wyeth
- 16 Aug 2017 Results (n=4279) of post-hoc pooled analysis of this and other eight double blind, placebo controlled studies, published in the Journal of Clinical Psychopharmacology.
- 19 Jul 2013 Results from a pooled analysis of six studies (NCT00277823, NCT00300378, NCT00384033, NCT00798707, NCT00824291, and NCT00863798) were published in the International Clinical Psychopharmacology.
- 10 Jun 2010 Primary endpoint results presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum